NICE National Institute for Health and Care Excellence

Resource impact summary report

Resource impact

Published: 10 July 2025

www.nice.org.uk

Contents

Resource impact summary report 3
Recommendation 3
Eligible population for zanubrutinib 3
Treatment options for the eligible population 4
Financial resource impact (cash items) 4
Capacity impact 5
Key information 5
About this resource impact summary report 5

Resource impact summary report

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.

Recommendation

Zanubrutinib can be used as an option to treat relapsed or refractory mantle cell lymphoma in adults who have had 1 line of treatment only. Zanubrutinib can only be used if the company provides it according to the commercial arrangement.

Use the least expensive option of the available treatments (including zanubrutinib and ibrutinib), having discussed the advantages and disadvantages of the available treatments. When considering the costs, take account of administration costs, dosages, price per dose and commercial arrangements.

This recommendation is not intended to affect treatment with zanubrutinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop.

Eligible population for zanubrutinib

Table 1 shows the population who are eligible for zanubrutinib and the number of people who are expected to have zanubrutinib in each of the next 5 years, including forecast population growth.

Table 1 Population expected to be eligible for and have zanubrutinib in England

Eligible population and uptake	People eligible for zanubrutinib	Uptake for zanubrutinib (%)	People starting treatment each year (if applicable)	People continuing treatment from previous years (if applicable)	People having zanubrutinib each year
Current practice without zanubrutinib	234	0%	0	0	0
Year 1	236	25%	59	0	59
Year 2	238	50%	119	59	178
Year 3	240	50%	120	178	298
Year 4	242	50%	121	239	360
Year 5	245	50%	122	241	363

The following assumptions have been used to calculate the eligible population:

- the incidence of mantle cell lymphoma in England is around 520 people per year
- 44.84% of these people will have relapsed or refractory mantle cell lymphoma and will have had 1 line of therapy

The annual uptake of zanubrutinib is projected to be 50% by year 2, based on NICE's assumption of comparable efficacy.

Treatment options for the eligible population

The comparator treatment for the eligible population is ibrutinib. Both zanubrutinib and ibrutinib are administered orally.

For more information about the treatments, such as dose and average treatment duration, see the resource impact template.

Financial resource impact (cash items)

The company has a commercial arrangement. This makes zanubrutinib available to the NHS with a discount.

Users can input the confidential price of zanubrutinib and amend other variables in the resource impact template.

The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.

For further analysis or to calculate the financial impact of cash items, see the resource impact template.

Capacity impact

Evidence for zanubrutinib used in clinical practice also supports that zanubrutinib is likely to work as well as ibrutinib for this population and both treatments are administered orally.

The estimated treatment duration for zanubrutinib is 27.0 months, compared with 14.4 months for Ibrutinib. This is expected to lead to an increase in oral chemotherapy prescription appointments and oncology follow-up appointments.

For further analysis or to calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the resource impact template.

Key information

Table 2 Key information

Time from publication to routine commissioning funding	30 days
Programme budgeting category	PBC 012X
Commissioner	NHS England
Providers	NHS hospital trusts
Pathway position	Second line

About this resource impact summary report

This resource impact summary report accompanies the NICE technology appraisal guidance on zanubrutinib for treating relapsed or refractory mantle cell lymphoma and

should be read with it.

ISBN: 978-1-4731-7110-7